Key facts
- Notable investors include SC Launch, South Carolina Research Authority, 1824 Health Ventures, U.S. Department of Health and Human Services.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Leukogene Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Leukogene Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leukogene Therapeutics
Operator of an oncology-focused biotech company intended to accelerate the development of new therapeutics for patients with advanced-stage cancer. The company offers patients with resistant multiple myeloma a new therapeutic avenue, enabling patients to easily treat cancer without any surgery.
- Sector
- Healthcare
- HQ
- Charleston, SC, United States
- Founded
- 2012
- Employees
- 5
- Website
- leukogene.com/
- Ownership
- Privately Held (backing)
Leukogene Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leukogene Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leukogene Therapeutics in its N-PORT filings yet. We sweep new filings monthly.